8PO2
Discovery and Optimisation of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. Compound 33 bound to EGFRinsNPG [V948R]
Summary for 8PO2
Entry DOI | 10.2210/pdb8po2/pdb |
Descriptor | Epidermal growth factor receptor, 1-cyclopropyl-~{N}-[3-[1-(1-propanoylazetidin-3-yl)-4-pyridin-4-yl-pyrazol-3-yl]phenyl]imidazole-4-carboxamide (3 entities in total) |
Functional Keywords | egfr, exon 20 insertion, non-small cell lung cancer, oncology, signaling protein |
Biological source | Homo sapiens (human) |
Total number of polymer chains | 3 |
Total formula weight | 114286.88 |
Authors | Hargreaves, D. (deposition date: 2023-07-03, release date: 2024-06-05, Last modification date: 2024-06-19) |
Primary citation | Thomson, C.,Barton, P.,Braybrooke, E.,Colclough, N.,Dong, Z.,Evans, L.,Floc'h, N.,Guerot, C.,Hargreaves, D.,Khurana, P.,Li, S.,Li, X.,Lister, A.,McCoull, W.,McWilliams, L.,Orme, J.P.,Packer, M.J.,Swaih, A.M.,Ward, R.A.,Winlow, P.,Ye, Y. Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations. J.Med.Chem., 67:8988-9027, 2024 Cited by PubMed: 38770784DOI: 10.1021/acs.jmedchem.4c00227 PDB entries with the same primary citation |
Experimental method | X-RAY DIFFRACTION (2.28 Å) |
Structure validation
Download full validation report